WO2004111249A3 - Protein constructs containing caspase recognition sites - Google Patents

Protein constructs containing caspase recognition sites Download PDF

Info

Publication number
WO2004111249A3
WO2004111249A3 PCT/EP2004/006225 EP2004006225W WO2004111249A3 WO 2004111249 A3 WO2004111249 A3 WO 2004111249A3 EP 2004006225 W EP2004006225 W EP 2004006225W WO 2004111249 A3 WO2004111249 A3 WO 2004111249A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide sequence
recognition sites
constructs containing
protein constructs
caspase recognition
Prior art date
Application number
PCT/EP2004/006225
Other languages
French (fr)
Other versions
WO2004111249A2 (en
Inventor
Andrej Egorov
Original Assignee
Bogensberger
Andrej Egorov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bogensberger, Andrej Egorov filed Critical Bogensberger
Publication of WO2004111249A2 publication Critical patent/WO2004111249A2/en
Publication of WO2004111249A3 publication Critical patent/WO2004111249A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a nucleotide sequence encoding a recombinant protein product wherein the nucleotide sequence contains at least one sequence that encodes one or more caspase recognition sites and that is located in between and links together a first part of the nucleotide sequence encoding a first part of the protein product and a second part of the nucleotide sequence encoding a second part of the protein product. The invention further relates to viral vectors and recombinant viruses containing said nucleotide sequence, as well as to vaccines, particularly attenuated live vaccines, and compositions comprising said vectors or viruses.
PCT/EP2004/006225 2003-06-13 2004-06-09 Protein constructs containing caspase recognition sites WO2004111249A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03013509.9 2003-06-13
EP03013509 2003-06-13

Publications (2)

Publication Number Publication Date
WO2004111249A2 WO2004111249A2 (en) 2004-12-23
WO2004111249A3 true WO2004111249A3 (en) 2005-02-10

Family

ID=33547589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006225 WO2004111249A2 (en) 2003-06-13 2004-06-09 Protein constructs containing caspase recognition sites

Country Status (1)

Country Link
WO (1) WO2004111249A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101250005B1 (en) * 2010-12-31 2013-04-03 연세대학교 산학협력단 Method of preparing live viral vaccines by genetic engineering of viral genome
EP3063273B8 (en) 2013-10-28 2020-12-30 Blue Sky Vaccines GmbH Influenza virus vector for virotherapy
WO2016065174A1 (en) * 2014-10-22 2016-04-28 Seed Research And Development Llc Caspase probes for detection of apoptosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073437A1 (en) * 1999-05-27 2000-12-07 Merck Frosst Canada & Co. Assays for caspase activity using green fluorescent proteins
WO2001020989A1 (en) * 1999-09-22 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073437A1 (en) * 1999-05-27 2000-12-07 Merck Frosst Canada & Co. Assays for caspase activity using green fluorescent proteins
WO2001020989A1 (en) * 1999-09-22 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERKO BORIS ET AL: "Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice", JOURNAL OF VIROLOGY, vol. 75, no. 19, October 2001 (2001-10-01), pages 8899 - 8908, XP002309937, ISSN: 0022-538X *
KITTEL CHRISTIAN ET AL: "Rescue of influenza virus expressing GFP from the NS1 reading frame", VIROLOGY, vol. 324, no. 1, 20 June 2004 (2004-06-20), pages 67 - 73, XP004512673, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
WO2004111249A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2002057664A3 (en) Bacillus thuringiensis insecticidal proteins
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
HK1061566A1 (en) Proteins producing an altered immunogenic response and methods of making and using the same
WO2004074497A3 (en) Endomannosidases in the modification of glycoproteins in eukaryotes
WO2003011878A3 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2002097048A3 (en) ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
EP1988099A3 (en) Bacillus thuringiensis insecticidal proteins
WO2004075861A3 (en) Recombinant adeno-associated virus production
WO2001085932A3 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
WO2004067567A3 (en) Anti-dengue virus antibodies, compositions, methods and uses
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
EP2392655A3 (en) Coagulation factor VII polypeptides
WO2005024006A3 (en) Coagulation factor vii polypeptides
WO2004111249A3 (en) Protein constructs containing caspase recognition sites
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2004039834A3 (en) Recombinant protein variants
WO2005033265A3 (en) Optimized multi-epitope constructs and uses thereof
WO2003029289A3 (en) Fragements of heat shock proteins and their use
WO2003025781A3 (en) Router
WO2002022663A3 (en) Stress resistant retroviruses
WO1995030757A3 (en) Metalloproteases from fusarium and aspergillus having thermolysin-like activity
WO2005056051A3 (en) Hepatitis b vaccines and compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase